神经母细胞瘤的多方案联合序贯式化疗初探  

Treatment of Neuroblastoma With Consecutive Multi-protocol Chemotherapy

作　　者：郑修军[1] 董蒨[1] 江布先[1] 黄婉芬[1] 

机构地区：[1]青岛医学院附属医院小儿外科

出　　处：《中华小儿外科杂志》1995年第5期279-281,共3页Chinese Journal of Pediatric Surgery

基　　金：山东省教委资助

摘　　要：采用多方案联合序贯式化疗对７例Ⅲ、Ⅳ期的神经母细胞瘤患儿进行术前及术后化疗，使患儿的二年生存率达４２．８％，平均生存时间为６７０天。而传统化疗的患儿平均生存时间仅为２７４天，两组间差别具有显著意义（０．０２＜Ｐ＜０．０５）（时序检验），且多方案联合序贯式化疗组并未产生严重的化疗副作用。From July,1991 to June.1994,7 chileren with stage Ⅲ or stage Ⅳ neuroblastoma, aged from 2.5 to 11 years,were treated with consecutive multi-protocol chemotherapy both in preoperative and postoperative period.Two of them survived free from tumor for two years(the survival rate was 42.8%).The survival was 670 days on average.But those patients treated with the traditional chemotherapy,the survival time was only 274 days.There was remarkable difference between these two groups(0.02<P<0.05)(long rank test).In addition,no serious side effect was observed in the consecutive multi-protocol chemotherapy.

关 键 词：神经母细胞瘤 序贯化疗 联化疗 

分 类 号：R730.264[医药卫生—肿瘤]